Join the event trusted by enterprise leaders for nearly two decades. VB Transform brings together the people building real enterprise AI strategy. Learn more About one in three Americans, or 125 ...
Tuesday, the FDA approved DexCom Inc’s (NASDAQ:DXCM) Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM). The Dexcom Stelo Glucose Biosensor System is ...
After getting the green light from the FDA back in March, Dexcom today launched its first over-the-counter wearable continuous glucose biosensor, Stelo, in the U.S. market. The device is now available ...
San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing just under ...
Dexcom on Monday announced its new over-the-counter continuous glucose monitor Stelo is officially available for purchase in the U.S. Glucose is a type of sugar people receive from food, and it's the ...
Nearly six months after the Food and Drug Administration (FDA) approved Dexcom’s over-the-counter continuing glucose monitor (CGM), the company has launched the product. The CGM – dubbed Stelo – made ...
Blood glucose giant Dexcom has used CES 2024 to announce a new continuous glucose monitor (CGM) designed specifically for Type 2 diabetics who don’t use insulin – Dexcom Stelo. The Stelo still ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results